Archive \ Volume.14 2023 Issue 2

Parenteral Therapy in Domiciliary and Outpatient Setting: A Critical Review of the Literature

, ,

Abstract

The clinical homecare sector is often associated with high-cost drug parenteral (injectable) therapy treatments and has been rapidly growing in the United Kingdom (UK) at a 20% annual rate. It was estimated that this could further rise to 60% if extended to all medicines that are considered to be suitable for care at home. The latest data shows that the homecare medicines services sector continues to grow in number and complexity, with over 500,000 patients and a spend of UK£3.2 billion in 2021. Given the extent of the National Health Service (NHS) expenditure and the number of patients involved, it is essential to understand and explore the patients’ and HCPs’ experiences, views, and perceptions of this therapy. As identified during this literature review, homecare provides opportunities for improved cost savings and improved patient experience, but several issues have already been reported worldwide. Patient education, training, support, and regular supervision, as well as the competency of HCPs to manage these patients, have all been identified as factors that contribute to the success or failure of self-administration of parenteral therapy at home, which might impact treatment outcomes and adherence. This is an area that needs urgent research.


Downloads: 687
Views: 2195

How to cite:
Vancouver
Puzovic M, Morrissey H, Ball PA. Parenteral Therapy in Domiciliary and Outpatient Setting: A Critical Review of the Literature. Arch Pharm Pract. 2023;14(2):1-12. https://doi.org/10.51847/dhavVPyhAV
APA
Puzovic, M., Morrissey, H., & Ball, P. A. (2023). Parenteral Therapy in Domiciliary and Outpatient Setting: A Critical Review of the Literature. Archives of Pharmacy Practice, 14(2), 1-12. https://doi.org/10.51847/dhavVPyhAV

Download Citation
References

1.        Laupland KB, Valiquette L. Outpatient parenteral antimicrobial therapy. Can J Infect Dis Med Microbiol. 2013;24(1):9-11.

2.        Raevskaya AI, Belyalova AA, Shevchenko PP, Karpov SM, Mishvelov AE, Simonov AN, et al. Cognitive Impairments in a Range of Somatic Diseases. Diagnostics, Modern Approach to Therapy. Pharmacophore. 2020;11(1):136-41.

3.        Risso NA, Neyem A, Benedetto JI, Carrillo MJ, Farias A, Gajardo MJ, et al. A cloud-based mobile system to improve respiratory therapy services at home. J Biomed Inform. 2016;63:45-53. doi:10.1016/j.jbi.2016.07.006

4.        Zuizewind CA, van Kessel P, Kramer CM, Muijs MM, Zwiers JC, Triemstra M. Home-Based Treatment with Immunoglobulins: an Evaluation from the Perspective of Patients and Healthcare Professionals. J Clin Immunol. 2018;38(8):876-85. doi:10.1007/s10875-018-0566-z

5.        Chrysochoou EA, Hatziagorou E, Kirvassilis F, Tsanakas J. Home intravenous antibiotic therapy in children with cystic fibrosis: clinical outcome, quality of life and economic benefit. Hippokratia. 2016;20(4):279-83.

6.        NCHA. National Clinical Homecare Association. Resolving the e-prescribing Interoperability Challenge in Clinical and Medicines Homecare Services for NHS patients. 2019. Available from: https://www.clinicalhomecare.org/wp-content/uploads/2019/09/Resolving_the_e-prescribing_Interoperability_Challenge_in_Clinical_and_Medicines_Homecare_Services_final220719.pdf (Accessed 07/03/2023)

7.        Hackett M. Homecare Medicines: Towards a Vision for the Future. University Hospital Southampton NHS Foundation Trust: Department of Health; 2011. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/213112/111201-Homecare-Medicines-Towards-a-Vision-for-the-Future2.pdf  (Accessed 07/03/2023)

8.        Davis A, Gibert S. CPC 2022 PROGRAMME: Homecare Medicines Services: The Future for the NHS and patients (National Homecare Medicines Committee, NHMC). 2022. Available from: https://www.pharmacycongress.co.uk/cpc-2022-programme/review-of-homecare-services-for-england-delivered-by-nhmc (Accessed 07/03/2023)

9.        Potera C. Misuse of Autoinjectors and Inhalers. AJN Am J Nurs. 2015;115(3):17. doi:10.1097/01.NAJ.0000461799.44904.d3

10.      Reynolds J. Enhancing the patient experience for self-injection systems. ONdrugDelivery Magazine. 2020(105):36-40.

11.      Murphy MK, Gura KM, Tascione C, Carey AN, Duggan CP, Raphael BP. Home Parenteral Nutrition and Intravenous Fluid Errors Discovered Through Novel Clinical Practice of Reconciling Compounding Records: A Case Series. Nutr Clin Pract. 2017;32(6):820-5. doi:10.1177/0884533617722759

12.      Staun M, Pironi L, Bozzetti F, Baxter J, Forbes A, Joly F, et al., ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients. Clin Nutr. 2009;28(4):467-79. doi:10.1016/j.clnu.2009.04.001.

13.      Pironi L, Arends J, Baxter J, Bozzetti F, Pelaez RB, Cuerda C, et al., ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr. 2015;34(2):171-80. doi:10.1016/j.clnu.2014.08.017

14.      Pironi L, Steiger E, Brandt C, Joly F, Wanten G, Chambrier C, et al., Home parenteral nutrition provision modalities for chronic intestinal failure in adult patients: An international survey. Clin Nutr. 2020;39(2):585-91. doi:10.1016/j.clnu.2019.03.010

15.      Theilla M, Kagan I, Chernov K, Cohen J, Kagan I, Singer P. Self-Evaluation of Quality of Life Among Patients Receiving Home Parenteral Nutrition: A Validation Study. JPEN J Parent Ent Nutr. 2017;42(3):516-21. doi:10.1177/0148607117704812

16.      Huisman-de Waal G, Bazelmans E, van Achterberg T, Jansen J, Sauerwein H, Wanten G, et al. Predicting fatigue in patients using home parenteral nutrition: a longitudinal study. Int J Behav Med. 2011;18(3):268-76. doi:10.1007/s12529-010-9116-7

17.      Hojsak I, Kolacek S. Fat overload syndrome after the rapid infusion of SMOFlipid emulsion. JPEN J Parent Ent Nutr. 2014;38(1):119-21. doi:10.1177/0148607113482001

18.      Buchman AL, Opilla M, Kwasny M, Diamantidis TG, Okamoto R. Risk factors for the development of catheter-related bloodstream infections in patients receiving home parenteral nutrition. JPEN J Parent Ent Nutr. 2014;38(6):744-9. doi:10.1177/0148607113491783

19.      Baxter JP, Fayers PM, Bozzetti F, Kelly D, Joly F, Wanten G, et al. An international study of the quality of life of adult patients treated with home parenteral nutrition. Clin Nutr. 2019;38(4):1788-96. doi:10.1016/j.clnu.2018.07.024

20.      Miller TL, Greene GW, Lofgren I, Greaney ML, Winkler MF. Content Validation of a Home Parenteral Nutrition-Patient-Reported Outcome Questionnaire. Nutr Clin Pract. 2017;32(6):806-13. doi:10.1177/0884533617725041

21.      Al-Ahmad M, Maher A, Nurkic J. Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy. Egypt J Intern Med. 2017;29(2):77. doi:10.4103/ejim.ejim217

22.      Kearns S, Kristofek L, Bolgar W, Seidu L, Kile S. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry. J Manag Care Spec Pharm. 2017;23(4):400-6. doi:10.18553/jmcp.2017.23.4.400

23.      Lechanska-Helman J, Sobocinska A, Jerzynska J, Stelmach I. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with Primary Immunodeficiency Diseases on their parents/caregivers satisfaction. Pediatr Int. 2020;62(3):316-8. doi:10.1111/ped.14119

24.      Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency. Vox Sang. 2019;114(3):237-46. doi:10.1111/vox.12760

25.      Bal K, Kaluzinska-Parzyszek I, Sobocinska A, Podlecka D, Jerzynska J, Stelmach I. Efficacy and Safety of Hospital-Based Intravenous Immunoglobulin and Home-Based Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases. Indian J Pediatr. 2015;82(8):768-9. doi:10.1007/s12098-015-1731-5

26.      Pasquet M, Pellier I, Aladjidi N, Auvrignon A, Cherin P, Clerson P, et al. A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions? Patient Prefer Adherence. 2017;11:1171-80. doi:10.2147/PPA.S123363

27.      Twiddy M, Czoski Murray CJ, Mason SJ, Meads D, Wright JM, Mitchell ED, et al. A qualitative study of patients' feedback about Outpatient Parenteral Antimicrobial Therapy (OPAT) services in Northern England: implications for service improvement. BMJ Open. 2018;8(1):e019099. doi:10.1136/bmjopen-2017-019099

28.      Keller SC, Cosgrove SE, Arbaje AI, Chang RH, Krosche A, Williams D, et al. It's Complicated: Patient and Informal Caregiver Performance of Outpatient Parenteral Antimicrobial Therapy-Related Tasks. Am J Med Qual. 2020;35(2):133-46. doi:10.1177/1062860619853345

29.      Carter B, Fisher-Smith D, Porter D, Lane S, Peak M, Taylor-Robinson D, et al. Being 'at-home' on outpatient parenteral antimicrobial therapy (OPAT): a qualitative study of parents' experiences of paediatric OPAT. Arch Dis Child. 2020;105(3):276-81. doi:10.1136/archdischild-2019-317629

30.      Glick AF, Farkas JS, Nicholson J, Dreyer BP, Fears M, Bandera C, et al., Parental Management of Discharge Instructions: A Systematic Review. Pediatrics. 2017;140(2):e20164165. doi:10.1542/peds.2016-4165

31.      Bartz L, Klein C, Seifert A, Herget I, Ostgathe C, Stiel S. Subcutaneous administration of drugs in palliative care: results of a systematic observational study. J Pain Symptom Manage. 2014;48(4):540-7. doi:10.1016/j.jpainsymman.2013.10.018

32.      Lee L, Howard K, Wilkinson L, Kern C, Hall S. Developing a policy to empower informal carers to administer subcutaneous medication in community palliative care; a feasibility project. Int J Palliat Nurs. 2016;22(8):369-78. doi:10.12968/ijpn.2016.22.8.369

33.      Healy S, Israel F, Charles MA, Reymond L. An educational package that supports laycarers to safely manage breakthrough subcutaneous injections for home-based palliative care patients: development and evaluation of a service quality improvement. Palliat Med. 2013;27(6):562-70. doi:10.1177/0269216312464262

34.      Thomas K, Hudson P, Oldham L, Kelly B, Trauer T. Meeting the needs of family carers: an evaluation of three home-based palliative care services in Australia. Palliat Med. 2010;24(2):183-91. doi:10.1177/0269216309351467

35.      Bowers B, Ryan R, Kuhn I, Barclay S. Anticipatory prescribing of injectable medications for adults at the end of life in the community: A systematic literature review and narrative synthesis. Palliat Med. 2019;33(2):160-77. doi:10.1177/0269216318815796

36.      Borras JM, Sanchez-Hernandez A, Navarro M, Martinez M, Mendez E, Ponton JLL, et al., Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomized controlled trial. BMJ. 2001;322(7290):826. doi:10.1136/bmj.322.7290.826

37.      Evans JM, Qiu M, MacKinnon M, Green E, Peterson K, Kaizer L. A multi-method review of home-based chemotherapy. Eur J Cancer Care (Engl). 2016;25(5):883-902. doi:10.1111/ecc.12408

38.      Yip F, Zavery B, Poulter-Clark H, Spencer J. Putting patients first: an inventive service delivering cancer treatment at home. J Comp Eff Res. 2019;8(12):951-60. doi:10.2217/cer-2019-0038

39.      Mittaine-Marzac B, De Stampa M, Bagaragaza E, Ankri J, Aegerter P. Impacts on health outcomes and on resource utilization of home-based parenteral chemotherapy administration: a systematic review protocol. BMJ Open. 2018;8(5):e020594-e. doi:10.1136/bmjopen-2017-020594

40.      Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. New Engl J Med. 1999;341(7):468-75. doi:10.1056/nejm199908123410702

41.      Chester JG, Bremberg MG, Reisacher WR. Patient preferences for route of allergy immunotherapy: a comparison of four delivery methods. Int Forum Allergy Rhinol. 2016;6(5):454-9. doi:10.1002/alr.21707

42.      Lyons MG, Carey L. Parenteral Inotropic Therapy in the Home: An Update for Home Care and Hospice. Home Healthc Now. 2013;31(4):190-204. doi:10.1097/NHH.0b013e3182885f77

43.      Tariq S, Aronow WS. Use of Inotropic Agents in Treatment of Systolic Heart Failure. Int J Mol Sci. 2015;16(12):29060-8. doi:10.3390/ijms161226147

44.      Piras V, Alves F, Goncalo M. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema. Dermatol Ther. 2019;32(6):e13098. doi:10.1111/dth.13098

45.      Zanichelli A, Azin GM, Cristina F, Vacchini R, Caballero T. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert(R)) in patients with hereditary angioedema: the SABHA study. Orphanet J Rare Dis. 2018;13(1):51. doi:10.1186/s13023-018-0797-3

46.      Squeglia V, Barbarino A, Bova M, Gravante C, Petraroli A, Spadaro G, et al. High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. Orphanet J Rare Dis. 2016;11(1):133. doi:10.1186/s13023-016-0518-8

47.      Bhardwaj N, Craig TJ. Treatment of hereditary angioedema: a review (CME). Transfusion. 2014;54(11):2989-96. doi:10.1111/trf.12674

48.      Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert J, Kanani A, et al. The International/Canadian Hereditary Angioedema Guideline. Allergy, Asthma, Clin Immunol. 2019;15:72. doi:10.1186/s13223-019-0376-8

49.      Li HH. Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance. Patient Prefer Adherence. 2016;10:1727-37. doi:10.2147/ppa.S86379

50.      Longhurst H. Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus. Front Med (Lausanne). 2018;4:245. doi:10.3389/fmed.2017.00245

51.      Whittlesea C, Hodson K. (eds) Clinical Pharmacy and Therapeutics. 6th ed: Edinburgh, Churchill Livingstone, 2019, pp 1112.

52.      Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15. doi:10.1038/s41413-018-0016-9

53.      van den Bemt BJF, Gettings L, Domańska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384-92. doi:10.1080/10717544.2019.1587043

54.      Schiff M, Saunderson S, Mountian I, Hartley P. Chronic Disease, and Self-Injection: Ethnographic Investigations into the Patient Experience During Treatment. Rheumatol Ther. 2017;4(2):445-63. doi:10.1007/s40744-017-0080-4

55.      Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9(1):2. doi:10.1186/1477-7525-9-2

56.      Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6(1):1-14. doi:10.1002/msc.110

57.      Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019;26(1):27-40. doi:10.1111/ene.13819

58.      Hočevar K, Ristić S, Peterlin B. Pharmacogenomics of Multiple Sclerosis: A Systematic Review. Front Neurol. 2019;10(134). doi:10.3389/fneur.2019.00134

59.      Popescu BFG, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013;19(4 Multiple Sclerosis):901-21. doi:10.1212/01.CON.0000433291.23091.65

60.      Mohammed EM. Environmental Influencers, MicroRNA, and Multiple Sclerosis. J Cent Nerv Syst Dis. 2020;12:1179573519894955. doi:10.1177/1179573519894955

61.      Alharbi FM. Update in vitamin D and multiple sclerosis. Neurosciences (Riyadh). 2015;20(4):329-35. doi:10.17712/nsj.2015.4.20150357

62.      Raffel J, Wakerley B, Nicholas R. Multiple sclerosis. Medicine. 2016;44(9):537-41. doi:10.1016/j.mpmed.2016.06.005

63.      Hansen K, Schussel K, Kieble M, Werning J, Schulz M, Friis R, et al., Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. PLoS One. 2015;10(7):e0133279. doi:10.1371/journal.pone.0133279

64.      Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, et al., Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256(4):568-76. doi:10.1007/s00415-009-0096-y

65.      Rieckmann P, Schwab M, Pohlau D, Penner IK, Wagner T, Schel E, et al. Adherence to Subcutaneous IFN beta-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart((R)). Adv Ther. 2019;36(1):175-86. doi:10.1007/s12325-018-0839-1

66.      Verdun di Cantogno E, Tomlinson M, Manuel L, Thakur K. Autoinjector preference in multiple sclerosis and the role of nurses in treatment decisions: results from an international survey in Europe and the USA. Pragmat Obs Res. 2014;5:53-64. doi:10.2147/por.s72012

67.      St Clair Jones A, Kelly M. Inflammatory bowel disease management. Clin Pharm. 2011;3:78-84.

68.      Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al., British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484

69.      NICE. National Institute for Health and Clinical Excellence. Infliximab and adalimumab for the treatment of Crohn's disease. NICE Technol Appraisal Guid [TA187]. 2010. Available from: https://www.nice.org.uk/guidance/ta187/resources/infliximab-and-adalimumab-for-the-treatment-of-crohns-disease-pdf-82598501180869 (Accessed 20/02/2023)

70.      Crohn's and Colitis UK [Internet]. Biologic medicines. Crohn's and Colitis UK; June 2019. Available from: https://www.crohnsandcolitis.org.uk/about-crohns-and-colitis/publications/biologic-medicines. (Accessed 20/02/2023)

71.      Pereira Guedes T, Pedroto I, Lago P. Vedolizumab-associated psoriasis: until where does gut selectivity go?. Rev Esp Enferm Dig. 2020;112(7):580-1. doi:10.17235/reed.2020.6817/2019

72.      Gilhooley E, Doherty G, Lally A. Vedolizumab-induced acne in inflammatory bowel disease. Int J Dermatol. 2018;57(6):752-3. doi:10.1111/ijd.14001

73.      Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol. 2013;11(7):826-31. doi:10.1016/j.cgh.2013.01.012

74.      Jonaitis L, Marković S, Farkas K, Gheorghe L, Krznarić Ž, Salupere R, et al. Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert's and patient's perspective. BMC Proc. 2021;15(Suppl 17):25. doi:10.1186/s12919-021-00230-7

75.      Allen PB, Lindsay H, Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol. 2010;10:1. doi:10.1186/1471-230X-10-1

76.      Apenteng PN, Fitzmaurice D, Litchfield I, Harrison S, Heneghan C, Ward A, et al. Patients' perceptions and experiences of the prevention of hospital-acquired thrombosis: a qualitative study. BMJ Open. 2016;6(12):e013839-e. doi:10.1136/bmjopen-2016-013839

77.      Mahlab-Guri K, Otman MS, Replianski N, Rosenberg-Bezalel S, Rabinovich I, Sthoeger Z. Venous thromboembolism prophylaxis in patients hospitalized in medical wards: A real-life experience. Medicine (Baltimore). 2020;99(7):e19127. doi:10.1097/MD.0000000000019127

78.      NICE. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE Guideline [NG89]. 2018. Available from: www.nice.org.uk/guidance/ng89 

79.      Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-9. doi:10.1161/01.Cir.0000138928.83266.24

80.      Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo-controlled trial. BMJ. 2006;332(7537):325-9. doi:10.1136/bmj.38733.466748.7C

81.      Wilke T, Moock J, Müller S, Pfannkuche M, Kurth A. Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery. Clin Orthop Relat Res. 2010;468(9):2437-53. doi:10.1007/s11999-010-1306-8

82.      Fanikos J, Stevens LA, Labreche M, Piazza G, Catapane E, Novack L, et al. Adherence to pharmacological thromboprophylaxis orders in hospitalized patients. Am J Med. 2010;123(6):536-41. doi:10.1016/j.amjmed.2009.11.017

83.      Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750-1172-5-30

84.      Concolino D, Amico L, Cappellini MD, Cassinerio E, Conti M, Donati MA, et al. Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group. Mol Genet Metab Rep. 2017;12:85-91. doi:10.1016/j.ymgmr.2017.06.005

85.      Cousins AJ. Improving compliance and quality of life with home infusions for the treatment of fabry disease. Clin Ther. 2009;31:S12-S3. doi:10.1016/S0149-2918(09)00242-2

86.      Kosmas CE, Silverio D, Ovalle J, Montan PD, Guzman E. Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient Prefer Adherence. 2018;12:2263-6. doi:10.2147/ppa.S149423

87.      Handelsman Y, Lepor NE. PCSK9 Inhibitors in Lipid Management of Patients with Diabetes Mellitus and High Cardiovascular Risk: A Review. J Amer Heart Assoc. 2018;7(13):e008953. doi:10.1161/JAHA.118.008953

88.      McDonagh M, Peterson K, Holzhammer B, Fazio S. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. J Manag Care Spec Pharm. 2016;22(6):641-53. doi:10.18553/jmcp.2016.22.6.641

89.      NICE. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE Technology appraisal guidance [TA393]. 2016. Available from: www.nice.org.uk/guidance/ta393(Accessed 10/02/2023)

90.      NICE. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE Technology appraisal guidance [TA394]. 2016. Available from: www.nice.org.uk/guidance/ta394 (Accessed 20/02/2023)

91.      Dent R, Joshi R, Stephen Djedjos C, Legg J, Elliott M, Geller M, et al., Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. SpringerPlus. 2016;5:300. doi:10.1186/s40064-016-1892-3

92.      NICE. Psoriasis: assessment and management. NICE Guidelines [CG153]. 2012. Available from: https://www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-pdf-35109629621701 (Accessed 20/02/2023)

93.      Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475

94.      Alcusky M, Lee S, Lau G, Chiu GR, Hadker N, Deshpande A, et al., Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis. Dermatol Ther (Heidelb). 2017;7(4):463-83. doi:10.1007/s13555-017-0205-2.

95.      Bolt T, Kobayashi H, Mahlich J. Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan. Pharmacoecon Open. 2019;3(2):255-64. doi:10.1007/s41669-018-0104-1

96.      SIGN. Diagnosis and management of psoriasis and psoriatic arthritis in adults, SIGN Guidelines (121). 2010. Available from: https://www.sign.ac.uk/assets/sign121.pdf (Accessed 20/02/2023)

97.      Thorneloe RJ, Bundy C, Griffiths CEM, Ashcroft DM, Cordingley L. Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. Br J Dermatol. 2017;176(3):667-76. doi:10.1111/bjd.15086

98.      Zhang M, Brenneman SK, Carter CT, Essoi BL, Farahi K, Johnson MP, et al. Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Prefer Adherence. 2015;9:777-84. doi:10.2147/PPA.S85773

99.      Kumpf VJ, Tillman EM. Home parenteral nutrition: safe transition from hospital to home. Nutr Clin Pract. 2012;27(6):749-57. doi:10.1177/0884533612464888

100.   Santaella ME, Bloomberg M, Anglade D. Home infusion teaching practices at federally funded hemophilia treatment centers in the United States of America. Res Pract Thromb Haemost. 2017;1(1):81-9. doi:10.1002/rth2.12020

 

 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.